40 results about "Streptococcus lactis" patented technology

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses application of a series of isosteviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative of the present invention, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the application of the derivative of the present invention provides the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The present application relates to a Pediococcus acidilactici capable of reducing the activation of hippocampal microglia cells and its application, belonging to the technical field of microorganisms. The Pediococcus acidilactici described in the present application is Pediococcus acidilactici CCFM1344, which was preserved in the Guangdong Microbial Culture Collection Center on September 12, 2023, with the preservation number GDMCC NO.63800. The preservation address is Building 59, 5th Floor, Guangdong Microbial Institute, 100 Middle Martyrs Road, Guangzhou. The Pediococcus acidilactici described in the present application can inhibit the over-activation of microglia cells caused by chronic stress, reduce the concentration of pro-inflammatory factors in the hippocampus of the brain, thereby relieving the activation of microglia cells in the hippocampus of the brain caused by chronic stress, and has excellent application prospects.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The present application relates to the technical field of microorganism, and particularly relates to a streptococcus lactis with a cat dandruff treatment function and application thereof. Pediococcus acidilactici The streptococcus lactis is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67035. The streptococcus lactis and the inactivated bacteria solution provided in the present application have good inhibitory effects on trichophyton mentagrophytes and mycosporum gypseum. The streptococcus lactis provided in the present application can also be used for treating cat dandruff, and compared with ketoconazole cream, the streptococcus lactis has faster effect and shorter treatment cycle.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The invention discloses a novel application of Xenocoumacin 1 in prevention and treatment of pathogenic bacteria of cow mastitis, and belongs to the field of natural pharmaceutical chemistry. According to the present invention, with the application of the Xenocoumacin 1, the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus), and the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus); therefore, the Xenocoumacin 1 has development potential in the aspect of being developed into the natural source medicine for preventing and treating the cow mastitis.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The present application relates to the field of aquaculture technology, in particular to a tilapia nilotica ferritin, a preparation method and application thereof, and a bacteriostatic agent.The amino acid sequence of the tilapia nilotica ferritin is shown as SEQ ID No.1, and the tilapia nilotica ferritin can inhibit Streptococcus agalactiae and / or Aeromonas hydrophila.The present application provides the tilapia nilotica ferritin, and in-vitro experiments have proved that the recombinant protein can effectively inhibit the proliferation of pathogenic bacteria.Further in-vivo experimental results show that the ferritin heavy chain (tilapia nilotica ferritin) has the important functions of inhibiting the proliferation of pathogenic bacteria and improving the survival rate of the organism, and plays an important role in the immune protection of the organism.

The invention discloses a compound cefquinome sulfate mammary gland perfusion agent and a preparation method thereof, and the compound cefquinome sulfate mammary gland perfusion agent comprises the following components in parts by mass: 60mg of cefquinome sulfate, 90mg of inositol, 80mg of a suspending aid, 120mg of a wetting agent, 4mg of an antioxidant, and the balance of a non-aqueous solvent, totaling 8g. The main drug in the preparation is a fourth-generation animal special cephalosporin antibiotic-cefquinome sulfate, has a broad-spectrum bactericidal effect and is effective to gram positive and gram negative strains including beta-lactamase-producing strains, and bacteriostasis experiments prove that the preparation has a strong antibacterial effect on various microorganisms causing cow mastitis, and can be used for preventing and treating cow mastitis. The composition especially has special effects on streptococcus uberis, streptococcus dysgalactiae, staphylococcus aureus and the like.

The invention relates to the technical field of biology, and particularly discloses streptococcus dysgalactiae and a preparation method and application of a streptococcus dysgalactiae egg yolk antibody, the streptococcus dysgalactiae is preserved in China General Microbiological Culture Collection Center on December 24, 2024, and the preservation number is CGMCC No.46272; the preparation method of the streptococcus dysgalactiae egg yolk antibody comprises the following steps: preparing a streptococcus dysgalactiae antigen, and carrying out vaccine distribution treatment on the antigen to obtain a streptococcus dysgalactiae vaccine; carrying out intramuscular injection on the chicken with a streptococcus dysgalactiae vaccine, and carrying out immune treatment; identifying the titer of the egg yolk, determining that the egg yolk accords with antibody preparation, then cleaning and disinfecting, and then air-drying; egg yolk and egg white are separated from the air-dried eggs, the egg yolk is pretreated with a disodium hydrogen phosphate solution, then acidification extraction, filtration sterilization and detection are conducted, and egg yolk antibodies are obtained; the compound is used for preventing and treating streptococcus dysgalactiae infection of pigs; the control effect is good.

The invention relates to the technical field of agricultural biology, in particular to application of protein 2370 in degradation of solanine. The amino acid sequence of the protein is shown as SEQ ID NO: 1. The streptococcus lactis strain SKLAN202403XW is obtained through identification and separation in potato planting soil, biological protein is obtained from the strain, solanine can be efficiently decomposed, the content of solanine can be remarkably reduced, the toxicity of potato stems and leaves is reduced, and a foundation is provided for subsequent development and utilization.

The invention discloses application of a series of steviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the derivative can be used for the preparation of the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The invention relates to the technical field of agricultural biology, in particular to application of a protein 0604 capable of efficiently degrading solanine to degradation of solanine. The amino acid sequence of the protein is shown as SEQ ID NO: 1. The streptococcus lactis strain SKLAN202403XW is obtained through identification and separation in potato planting soil, biological protein is obtained from the strain, solanine can be efficiently decomposed, the content of solanine can be remarkably reduced, the toxicity of potato stems and leaves is reduced, and a foundation is provided for subsequent development and utilization.

The application discloses a Pichia kluyveri strain, a Streptococcus lactis strain and application of co-fermentation of the two strains in coffee green bean degumming, and belongs to the technical field of microbial fermentation. The two strains (K123 and L135) are applied to co-fermentation in coffee green bean degumming, and can also be applied to preparation of coffee biological degumming preparation. When the compounding ratio of the strain compounding bacteria liquid is K123:L135=2:1, the fermentation temperature is 32 DEG C, the concentration is 10 7 CFU / mL, and the fermentation time is 36h, the pectinase activity can reach 982.985u / g, pectin can be effectively decomposed, biological degumming of coffee green beans can be realized, and the application prospect is good.

The invention belongs to the technical field of antibiotic enzymes, and relates to a recombinant antibiotic enzyme PlyTC37 as well as a coding gene and application thereof. The amino acid sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 1, and the coding nucleotide sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 2. The recombinant antibiotic enzyme PlyTC37 disclosed by the invention has a wider bactericidal spectrum, so that the recombinant antibiotic enzyme PlyTC37 has a killing effect on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa and gram-positive bacteria such as staphylococcus aureus, streptococcus agalactiae and streptococcus hemolyticus, the MIC value of the recombinant antibiotic enzyme PlyTC37 to acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa is about 20 [mu] g / ml. Meanwhile, the recombinant antibiotic enzyme PlyTC37 enables the load of acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa to be reduced by 4-5 logarithmic units in the presence of NaCl with physiological concentration, so that the clinical application prospect of the recombinant antibiotic enzyme PlyTC37 is remarkably improved.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to the technical field of disease prevention and control of aquatic animals, and particularly discloses a fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae and a preparation method and application thereof.The fermented traditional Chinese medicine composition is obtained by fermenting the following traditional Chinese medicine raw materials in parts by weight: 1.2-5 parts of radix scutellariae, 0.5-2.5 parts of fructus chebulae and 0.5-1 part of radix et rhizoma rhei. The preparation method comprises the following steps: adding the traditional Chinese medicine raw materials into a fermentation culture medium in parts by weight, then inoculating a mixed fermentation bacterial solution, and carrying out fermentation culture in an environment of 35-39 DEG C, so as to obtain the fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae after fermentation is completed. The proper traditional Chinese medicine raw material combination is selected and fermented, and the survival rate of the tilapia infected with streptococcus agalactiae can be remarkably increased through test evaluation.

The invention provides a method for purifying capsular polysaccharide of streptococcus agalactiae. According to the method, CTAB (cetyltrimethyl ammonium bromide) and impurities are removed through ethanol with different concentrations under the condition that salt ions (sodium ions or calcium ions) or not exist. In the whole process flow, phenol reagents which are high in harm to human bodies and environment and high in safety risk are prevented from being used, so that the safety of operators is effectively protected on the basis of ensuring the purification quality, and the damage of phenol to the environment is avoided. The capsular polysaccharide prepared by the invention has the advantages of high purity, low content of impurities such as endotoxin and nucleic acid, simplified steps, simple and controllable operation process, smaller batch-to-batch difference and better process stability, and is suitable for large-scale production.

The invention discloses lactobacillus acidophilus BT-C15 with inflammation relieving and mucosal barrier repairing functions and application of the lactobacillus acidophilus BT-C15, the lactobacillus acidophilus BT-C15 is preserved in the China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252625. The invention provides a brand new lactobacillus acidophilus BT-C15 which mainly has the effects of relieving inflammation and whitening the skin. The lactobacillus acidophilus BT-C15 has good tolerance to gastric juice and intestinal juice, is high in cell adhesion capacity, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can improve colitis, fade spots, whiten skin and improve autism, especially when the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 are used in a combined mode, the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 have a synergistic effect, and the improvement effect on the autism can be remarkably improved.

The present application relates to the field of biotechnology, and particularly relates to SNP marker combination for identifying resistance to streptococcus agalactiae disease of tilapia and application thereof. The present application discloses 11 SNP sites in UTRN gene of tilapia which are significantly related to resistance to streptococcus agalactiae disease, and constructs 18 SNP marker combinations for identifying resistance phenotype of streptococcus agalactiae disease, which can effectively improve the accuracy and genetic stability of resistance phenotype identification. In addition, the SNP typing primer and method based on MALDI-TOF mass spectrometry platform provided by the present application can realize high-throughput and high-precision genotyping, and has important application value in resistance phenotype identification and assisted selection breeding.

The invention discloses a deodorant and a preparation method thereof. The deodorant comprises the following components in parts by weight: 10%-20% of photosynthetic bacteria, 5%-15% of streptococcus lactis, 5%-15% of bacillus amyloliquefaciens, 10%-20% of proteolytic enzyme, 15%-25% of compound enzyme, 10%-20% of tartaric acid and 5%-15% of free fatty acid. By adopting the synergistic effect of various microorganisms, enzymes and chemical components, the deodorant is efficient in deodorization and can quickly remove various stink; environment-friendly and safe components are selected, pollution to the environment is avoided, harmful residues are avoided, and the water purifying agent can be safely used for various water bodies and does not harm aquatic organisms and human health; the water quality improvement function is achieved, organic pollutants can be decomposed, nutrients are balanced, and the water quality is improved; the formula is high in adaptability, has a good effect on different types of odor sources, and is wide in application range; the preparation process is scientific and reasonable, operation steps and parameters of all links are clear, stable and reliable quality is guaranteed, and large-scale production and popularization are facilitated.

The application discloses a bocachango Mob1b antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to the following steps: based on multi-omics method, an antibacterial peptide precursor gene sequence is screened and recognized from a bocachango multi-omics data set based on biological big data, and then the bocachango Mob1b antibacterial peptide amino acid sequence is obtained through translation design, as shown in SEQ ID NO: 3; through activity simulation prediction and in-vitro experiment verification, the bocachango Mob1b antibacterial peptide shows inhibitory effects on the growth activities of streptococcus agalactiae, salmonella enteritidis, staphylococcus aureus, vibrio anguillarum and escherichia coli; in particular, the bocachango Mob1b antibacterial peptide shows inhibitory effects on the gram-positive bacteria streptococcus agalactiae, the gram-negative bacteria escherichia coli, staphylococcus aureus and vibrio anguillarum, and the inhibitory effect can be shown at a concentration of 2.5 micromoles per liter, and the best inhibitory effect can be achieved at a concentration of 5 micromoles per liter, so that the bocachango Mob1b antibacterial peptide can be used for preparing various bactericidal preparations and the like, and has good practical value and social ecological benefits.

The application provides a tilapia antibacterial peptide OnLEAP-2 and an application thereof, and an antibacterial peptide named OnLEAP-2 is cloned from tilapia, and a large amount of the antibacterial peptide is obtained through prokaryotic expression. The antibacterial peptide has a good effect of resisting Streptococcus agalactiae, so that the survival rate of the tilapia is significantly improved, and pathogens are efficiently removed. The antibacterial peptide is suitable for the prevention and treatment of bacterial diseases of economic fishes such as tilapia.

The present application belongs to the technical field of genetic engineering, and particularly relates to a Streptococcus agalactiae Mu-20 and a construction method and application thereof. The present application constructs a fish-derived Streptococcus agalactiae strain with a capsule polysaccharide deficiency, no hyaluronidase activity, no hemolysis and no trehalose fermentation, and the strain number is Mu-20. The strain was preserved in the Guangdong Microbial Culture Collection Center on June 13, 2022, and the preservation number is GDMCC No: 62540. The strain does not carry a chloramphenicol resistance marker gene, has high biological safety, has no risk of virulence returning to strength, has high immunogenicity, can protect immunized fish against the invasion of Streptococcus agalactiae, and is easy to cultivate, simple to use and low in production cost. The strain involved in the present application can be used to prepare a live attenuated vaccine for fish streptococcosis, and has extremely high commercial application value.